Skip to main content
Premium Trial:

Request an Annual Quote

Personalis ACE ImmunoID NGS Services

Personalis has launched an expansion of its services to immune-oncology research and clinical trials with its Accuracy and Content Enhanced ImmunoID product. This product addresses shortcomings in typical NGS cancer offerings, such as sequence biases and gaps in gene coverage, and features leading-edge informatics pipelines supporting both RNA and DNA analysis as well as tumor-normal analysis to aid in the detection of neoantigens, Personalis said. ACE fills in NGS sequencing gaps through Personalis' enhanced targeted enrichment which optimizes sample prep and targeted capture in difficult-to-sequence regions, such as regions of high-GC content. The ACE cancer exome and ACE cancer panel augment over 1,600 cancer and immune-oncology genes as well as key non-coding regions. High-coverage ACE sequencing data provides sensitive detection of small variants and CNVs at low allele frequencies. In addition, RNA data from the same sample, targeted to the same gene set, is used to quantify gene expression — critical for immune-oncology applications — in addition to detecting gene fusions and confirming allelic expression.